University of Alabama-Birmingham
Welcome,         Profile    Billing    Logout  
 52 Trials 
53 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Carlo, Wally A
PRIORITY, NCT05590260: Prevention of Iron Deficiency Anemia Post-delivery

Recruiting
3
4800
RoW
IV iron infusion, Oral iron tablets
NICHD Global Network for Women's and Children's Health, Thomas Jefferson University, University of North Carolina, Chapel Hill, Kinshasa School of Public Health, University of Alabama at Birmingham, University Teaching Hospital, Lusaka, Zambia, University of Colorado, Denver, Institute of Nutrition of Central America and Panama, University of Virginia, International Centre for Diarrhoeal Disease Research, Bangladesh, Columbia University, Aga Khan University, Boston University, Lata Medical Research Foundation, Nagpur, Indiana University, Moi University, RTI International, Bill and Melinda Gates Foundation, KLE University Jawaharlal Nehru Medical College
Postpartum Anemia
10/25
12/25
NCT02742454: VentFirst: A Multicenter RCT of Assisted Ventilation During Delayed Cord Clamping for Extremely Preterm Infants

Active, not recruiting
N/A
570
Canada, US
Standard 30-60 Seconds Cord Clamping, VentFirst 120 Seconds Cord Clamping
University of Virginia, Brigham and Women's Hospital, Mayo Clinic, St. Louis University, University of Colorado, Denver, Oregon Health and Science University, University of Calgary, Columbia University, Indiana University, University of California, Davis, University of Alberta, University of Alabama at Birmingham
Intraventricular Hemorrhage
03/23
12/23
P3OPPY, NCT06510075: Providing an Optimized and Empowered Pregnancy for You (POPPY) Aim 3: Randomized Controlled Trial

Recruiting
N/A
400
US
Digital Health intervention, DHI, Community Health Worker, CHW, Digital Health Intervention plus Community Health Worker, DHI plus CHW
University of Alabama at Birmingham, American Heart Association, ConnectionHealth, Memora Health
Pregnancy Complications, Maternal Distress, Adverse Birth Outcomes, Infant Conditions
07/26
01/27
PREMOD2FU, NCT03476980: Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping)

Recruiting
N/A
1200
Europe, Canada, US
Randomized to Umbilical Cord Milking at birth, UCM, Randomized to Delayed Cord Clamping at birth, DCC
Sharp HealthCare, Sharp Mary Birch Hospital for Women & Newborns, Loma Linda University, University of Pittsburgh, Providence Hospital, University of Alabama at Birmingham, University of Alberta, University College Cork, University of Ulm, Christiana Care Health Services, Thrasher Research Fund, Sharp Grossmont Hospital, University of Utah, University of Mississippi Medical Center, PIH Health Good Samaritan Hospital, University of California, Irvine, Children's Hospital Medical Center, Cincinnati, John H. Stroger Hospital, St. Louis University, LAC+USC Medical Center
Neurodevelopmental Abnormality
12/24
12/24
Elie, Marie-Carmelle
ACTIV-4, NCT04505774 / 2020-004285-19: Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Completed
4
3591
Europe, US, RoW
theraputic heparin, unfractionated heparin, Enoxaparin, Dalteparin, Tinzaparin, Heparin, prophylactic heparin, enoxaparin, dalteparin, Fondparinux, P2Y12, Ticagrelor, Prasugrel, Clopidogrel, Crizanlizumab Injection, SGLT2 inhibitor, dapagliflozin, empagliflozin, canagliflozin, ertugliflozin
Matthew Neal MD, National Heart, Lung, and Blood Institute (NHLBI)
Covid19
08/23
01/24
ARREST, NCT04193878: ARrest RESpiraTory Failure From PNEUMONIA

Recruiting
3
600
US
Inhaled budesonide and formoterol, Pulmicort Respules (budesonide) and Perforomist (formoterol), Inhaled placebo, aerosolized 0.9% saline
Stanford University, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)
Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
07/25
08/25
NCT03133208: Sepsis Associated Encephalopathy (SAE) Biomarkers

Active, not recruiting
N/A
90
US
Blood draws
University of Florida
Sepsis, Altered Mental Status, Sepsis-Associated Delirium, Sepsis Associated Encephalopathy, Delirium, Sepsis Associated
07/25
07/25
NCT02372734: Long Term Cognitive Impact of Pediatric Acute Renal Injury

Active, not recruiting
N/A
400
US
Pediatric Quality of Life (Peds QL) Survey
University of Florida, American Society of Nephrology
Acute Kidney Injury
04/25
04/25
Garvey, Timothy
NCT04595968: Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control As a Means of Improving Glycemic Control in Adults with Type 2 Diabetes Mellitus

Completed
N/A
267
Europe, US
Vestal DM Active device, Lifestyle modification, Vestal DM Sham device
Neurovalens Ltd., University College Dublin, CS Lifescience, Clinical Trial Mentors
Type 2 Diabetes
08/24
08/24
Cherrington, Andrea
NCT04343872: Preventing Diabetes in the Deep South: Extending Partnerships and Adapting Interventions to Reach Rural Communities at High Risk.

Completed
N/A
36
US
Receive lifestyle modification alone, Metformin therapy
University of Alabama at Birmingham, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pre-diabetes
12/22
12/22
EPIPHANY, NCT05367544: Equity in Prevention and Progression of Hypertension by Addressing Barriers to Nutrition and Physical activitY

Recruiting
N/A
528
US
Health Education, Individual-Level Peer Support, Community-Level Peer Support
University of Alabama at Birmingham
Prehypertension, Hypertension, Blood Pressure
07/25
09/25
Savona, Michael
VITAL, NCT02658487: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

Active, not recruiting
2
42
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Vosaroxin, AG-7352, SNS-595, SPC 595, Voreloxin
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
04/19
09/24
NCT03238248: Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Completed
2
71
US
Azacitidine Subcutaneous Injection or Intravenous Infusion, Pevonedistat Infusion, Bone Marrow Biopsy & Aspirate
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Myelodysplastic Syndromes, Myeloproliferative Neoplasm
09/22
11/23
ABNL-MARRO, NCT04061421: Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes

Recruiting
1/2
105
US
ASTX727, Fixed dose combination of cedazuridine (100mg) + oral decitabine (35mg), Itacitinib, INCB039110
Michael Savona, Incyte Corporation, Theradex, Astex Pharmaceuticals, Inc.
MDS/MPN
08/24
08/25
NCI-2021-02246, NCT04817241: Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Active, not recruiting
1/2
55
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin, Daunomycin, Daunorrubicina, DNR, Leukaemomycin C, Rubidomycin, Rubomycin C, Decitabine and Cedazuridine, ASTX 727, ASTX-727, ASTX727, C-DEC, CDA Inhibitor E7727/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Combination Agent ASTX727, Cedazuridine/Decitabine Tablet, DEC-C, Inaqovi, Inqovi, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia
10/25
10/25
NCT02493530: TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Completed
1
60
US
TGR-1202, ruxolitinib, Jakafi
Vanderbilt-Ingram Cancer Center
Myelofibrosis, Polycythemia Vera
03/23
05/24
FHD-286-C-002, NCT04891757: FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Recruiting
1
144
US
FHD-286, Low Dose Cytarabine, LDAC, Decitabine
Foghorn Therapeutics Inc.
Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia
09/25
06/27
NCT03906344: Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis

No Longer Available
N/A
NA
INCB052793
Incyte Corporation
 
 
Jordan, William
stAAAble, NCT06001918: Nectero EAST System Clinical Study

Recruiting
2/3
400
US
Nectero EAST System
Nectero Medical, Inc.
Abdominal Aortic Aneurysm
03/27
12/29
NCT01534819: ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)

Active, not recruiting
N/A
1090
Europe, US, RoW
EndoAnchor™, Heli-FX™, Heli-FX™ EndoAnchor™ System, endovascular treament
Medtronic Cardiovascular
Aortic Aneurysm
12/20
12/25
TAMBE, NCT05442489: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms

Approved for marketing
N/A
US
GORE Excluder Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aneurysm
 
 
SSB 11-02, NCT02777528: Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 0/1)

Active, not recruiting
N/A
150
Japan, US
GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure
W.L.Gore & Associates
Aortic Aneurysm, Thoracic, Aorta, Lesion
03/24
03/28
TAMBE, NCT03728985: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

Active, not recruiting
N/A
102
Europe, US
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aortic Aneurysm
01/23
09/26
Melby, Spencer
NCT05076604: Effects of Microplegia on Transfusion Rates After Cardiac Surgery

Completed
4
314
US
Cardioplegia Solution, Microplegic Solution No. 1
Washington University School of Medicine, Quest Medical, Inc
Aortic Valve Disease, Mitral Valve Disease
06/23
08/23
Wallace, Eric L
PERIDOT, NCT05206773 / 2021-002350-90: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Active, not recruiting
3
122
Europe, Canada, Japan, US, RoW
Venglustat (GZ402671), Placebo
Sanofi, Sanofi-Aventis Recherche & Développement
Fabry Disease
12/25
12/26
NCT04552691: Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

Approved for marketing
N/A
US
Pegunigalsidase Alfa
Chiesi Farmaceutici S.p.A., Chiesi USA, Inc.
Fabry Disease
 
 
FROST-HF, NCT05136820: Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study

Active, not recruiting
N/A
698
US
Atrial Flow Regulator, AFR, Sham Comparator
Occlutech International AB
Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)
02/26
02/29
Yang, Eddy
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
NRG-HN006, NCT04333537: Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Recruiting
2/3
618
Canada, US
Computed Tomography (CT), CAT, CAT scan, Computed Tomography, computerized axial tomography, Computerized Tomography, CT, CT scan, tomography, Imaging Agent, Image Enhancement Agent, Neck Dissection, Planar Imaging, Sentinel Lymph Node Biopsy, Sentinel Node Biopsy, Sentinel node biopsy alone, SLNB, SNB, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon
NRG Oncology, National Cancer Institute (NCI)
Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
05/31
05/36
TBCRC 048, NCT03344965: Olaparib in Metastatic Breast Cancer

Active, not recruiting
2
114
US
Olaparib, AZD2281, KU-0059436
Beth Israel Deaconess Medical Center, Johns Hopkins University, AstraZeneca, Dana-Farber Cancer Institute
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
07/25
12/25
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
06/26
06/27
RAD 1805, NCT04298983: Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer

Active, not recruiting
2
9
US
Abemaciclib 150 MG by mouth twice daily, Androgen deprivation therapy (ADT), Radiation Therapy
University of Alabama at Birmingham
Prostate Cancer
04/25
04/26
NCT05283330: Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Recruiting
1
30
US
²¹²Pb-DOTAM-GRPR1
Orano Med LLC
Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
08/24
01/25
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32
Erba, Harry Paul
VITAL, NCT02658487: Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

Active, not recruiting
2
42
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Vosaroxin, AG-7352, SNS-595, SPC 595, Voreloxin
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Multilineage Dysplasia, Myeloid Sarcoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
04/19
09/24
Forero, Andres
NCT02158507: Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Completed
N/A
23
US
Combination of Veliparib + Lapatinib, Veliparib (ABT-888), Lapatinib (Tykerb)
University of Alabama at Birmingham, Breast Cancer Research Foundation of Alabama, GlaxoSmithKline, AbbVie
Metastatic Triple Negative Breast Cancer
07/21
07/21
Subramaniam, Akila
PRISM, NCT06377098: Intrapartum Sildenafil in Laboring Mothers

Not yet recruiting
2
1000
RoW
Sildenafil 50 mg Oral Tablet, Revatio, Sildenafil, Placebo Oral Tablet
University of Alabama at Birmingham, University Teaching Hospital, Lusaka, Zambia, Egerton University, Cameroon Baptist Convention Health
Neonatal Asphyxia, Intrapartum Fetal Distress, Development, Infant, Intrapartum Asphyxia
08/26
09/28
EXPAND, NCT06808880: EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders

Recruiting
N/A
4000
US
Single-gene Noninvasive Prenatal Testing (sgNIPT)
Natera, Inc.
Single Gene NIPT
11/25
02/26
Garcia, Jacob
UB-VV111-01, NCT06528301: A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Recruiting
1
106
US
UB-VV111, rapamycin, Rapamune, sirolimus
Umoja Biopharma
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
04/29
04/29
Drewes, Wendy
REACT-AF, NCT05836987: The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

Recruiting
3
5350
US
AFSW Guided DOAC, Apple Watch, Continuous DOAC therapy, Oral Anticoagulation therapy
Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI)
Atrial Fibrillation
07/29
07/29
NCT02905357: Heart Attack Research Program- Imaging Study

Recruiting
N/A
450
Canada, US
OCT, CMR
NYU Langone Health
Myocardial Infarction
06/26
06/26
DEFINE AFib, NCT04926857: (Atrial Fibrillation)

Completed
N/A
973
US
Non-Interventional
Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
01/24
01/24
Solomon, George M
BMX-04-001, NCT05010577 / 2022-003810-35: Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

Active, not recruiting
1b/2a
32
Europe, US, RoW
BX004-A, Bacteriophage, Placebo, Vehicle buffer
BiomX, Inc., BiomX Ltd.
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
10/23
03/24
AEROW, NCT05248230: 4D-710 in Adult Patients with Cystic Fibrosis

Recruiting
1/2
40
US
4D-710
4D Molecular Therapeutics
Cystic Fibrosis Lung
12/26
01/30
NCT03587961: Personalized Theratyping Trial

Recruiting
1
20
US
Symdeko, Orkambi, Ivacaftor
University of Alabama at Birmingham
Cystic Fibrosis
01/26
09/26
HFCWO, NCT04271969: Clinical Effectiveness Of High Frequency Chest Wall Oscillation () In A Bronchiectasis Population

Completed
N/A
25
US
SmartVest Airway Clearance System
Electromed, Inc., University of Alabama at Birmingham
Bronchiectasis
12/23
12/23
HOPeCF, NCT06296394: Health Outcomes of Parents With Cystic Fibrosis-Aim 2

Recruiting
N/A
146
US
Parenthood
University of Pittsburgh, Cystic Fibrosis Foundation, National Heart, Lung, and Blood Institute (NHLBI)
Cystic Fibrosis, Parenthood Status
02/30
02/31
RARE, NCT03161808: Rare CFTR Mutation Cell Collection Protocol

Recruiting
N/A
500
US
George Solomon, Cystic Fibrosis Foundation
Cystic Fibrosis
12/25
12/26
Mehta, Amit K
NCT05414500: Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Recruiting
1
10
US
Mogamulizumab, Brentuximab vedotin
University of Alabama at Birmingham, Seagen Inc., Kyowa Kirin, Inc.
Cutaneous T Cell Lymphoma, Mycosis Fungoides
04/26
07/26
ASCEND, NCT05388708: ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment

Recruiting
N/A
550
Europe, Canada, US, RoW
ECMO support, PROSpect protocolized therapies
University of Michigan, National Heart, Lung, and Blood Institute (NHLBI)
Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
09/27
09/27
Hua, May
ICUconnect 2, NCT06588556: Improving Needs Among Older Adults

Not yet recruiting
N/A
350
US
ICUconnect, Usual care
Duke University, National Institute on Aging (NIA)
Critical Illness, Palliative Care, Older Adults, Informal Caregivers, Care Delivery Model
08/28
12/28
Kloda, David
NCT05255757: Network Interventions to Reduce Disparities in Living Kidney Donation

Completed
N/A
164
US
Script Intervention, Search Intervention
Penn State University, University of Pennsylvania, University of Alabama at Birmingham
End-stage Renal Disease
05/24
05/24

Download Options